Skip to main content

Table 3 Distribution of treatments according to molecular diagnosis

From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Molecular diagnosis

Treatment

Distribution

ALK+

Alectinib

95%

Crizotinib

5%

EFGR+

Erlotinib

3,3%

Gefitinib

6,7%

Afatinib

11.7%

Osimertinib

76.3%

Dacomitinib

2%

ROS1+

Crizotinib

95% (40%a)

Clinical trials

5%

Entrectinib

0% (55%a)

WT

 TPS ≥50%

Pembrolizumab monotherapy

90%

Cisp+pmtrx

5%

Clinical trials

5%

 TPS < 50%

Cisp+pmtrx

25%

Carb+paclitx+beva

5%

Cisp+pmtrx+pembrolizumab

60%

Carb+ paclitx +beva+atezolizumab

10%

  1. EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, ROS1 C-ros oncogene 1, WT Wild-type, TPS Tumour proportion score, Cisp Cisplatin, Carb Carboplatin, pmtrx Pemetrexed, paclitx Paclitaxel, beva Bevacizumab
  2. aDistribution considered in the alternative scenario in which entrectinib is a treatment alternative in ROS1-positive patients